These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

139 related items for PubMed ID: 3736679

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Identification of dopamine "D3" and "D4" binding sites, labelled with [3H]2-amino-6,7-dihydroxy-1,2,3,4-tetrahydronaphthalene, as high agonist affinity states of the D1 and D2 dopamine receptors, respectively.
    Urwyler S, Markstein R.
    J Neurochem; 1986 Apr; 46(4):1058-67. PubMed ID: 2936868
    [Abstract] [Full Text] [Related]

  • 10. Further in vitro and in vivo studies with the putative presynaptic dopamine agonist N,N-dipropyl-7-hydroxy-2-aminotetralin.
    Mulder TB, de Vries JB, Dijkstra D, Wiechers JW, Grol CJ, Horn AS.
    Naunyn Schmiedebergs Arch Pharmacol; 1987 Nov; 336(5):494-501. PubMed ID: 2830544
    [Abstract] [Full Text] [Related]

  • 11. Striatal binding of 2-amino-6,7-[3H]dihydroxy-1,2,3,4-tetrahydronaphthalene to two dopaminergic sites distinguished by their low and high affinity for neuroleptics.
    List SJ, Wreggett KA, Seeman P.
    J Neurosci; 1982 Jul; 2(7):895-906. PubMed ID: 6124583
    [Abstract] [Full Text] [Related]

  • 12. Kinetic and pharmacological profiles of the in vitro binding of the potent dopamine agonist [3H]N,N-dipropyl-5,6-dihydroxy-2-aminotetralin to rat striatal membranes.
    Mulder TB, Grol CJ, Dijkstra D, Horn AS.
    Eur J Pharmacol; 1985 May 28; 112(1):73-9. PubMed ID: 4018139
    [Abstract] [Full Text] [Related]

  • 13. [3H] 2-Amino-6,7-dihydroxy 1,2,3,4-tetrahydronapthalene (ADTN): a potential specific dopamine receptor ligand.
    Clement-Cormier Y, Abel M.
    Res Commun Chem Pathol Pharmacol; 1978 Oct 28; 22(1):15-25. PubMed ID: 725314
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. A prodrug of ADTN: selectivity of dopaminergic action and brain levels of ADTN.
    Horn AS, Kelly P, Westerink BH, Dijkstra D.
    Eur J Pharmacol; 1979 Nov 23; 60(1):95-9. PubMed ID: 574829
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Synthesis and dopaminergic activity of some halogenated mono- and dihydroxylated 2-aminotetralins.
    Weinstock J, Gaitanopoulos DE, Oh HJ, Pfeiffer FR, Karash CB, Venslavsky JW, Sarau HM, Flaim KE, Hieble JP, Kaiser C.
    J Med Chem; 1986 Sep 23; 29(9):1615-27. PubMed ID: 2875183
    [Abstract] [Full Text] [Related]

  • 18. Ascorbic acid and membrane ageing: critical determinants of the in-vitro binding of [3H]ADTN to rat striatal tissue.
    Bradbury AJ, Costall B, Naylor RJ.
    J Pharm Pharmacol; 1983 Nov 23; 35(11):738-45. PubMed ID: 6139456
    [Abstract] [Full Text] [Related]

  • 19. Resolution of 5,6-dihydroxy-2-(N,N-di-n-propylamino)tetralin in relation to the structural and stereochemical requirements for centrally acting dopamine agonists.
    Grol CJ, Jansen LJ, Rollema H.
    J Med Chem; 1985 May 23; 28(5):679-83. PubMed ID: 4039369
    [Abstract] [Full Text] [Related]

  • 20. The significance of COMT activity in controlling dopamine agonist levels in brain and serum: studies with a prodrug and a metabolite of 6,7-ADTN.
    Rollema H, Westerink BH, Mulder TB, Dijkstra D, Feenstra MG, Horn AS.
    Eur J Pharmacol; 1980 Jun 27; 64(4):313-23. PubMed ID: 7389825
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.